Everolimus (RAD001) in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab: a multicenter phase I clinical trial

被引：0
|
作者：
Hurvitz, S. [1 ]
O'Regan, R. [2 ]
Campone, M. [3 ]
Manlius, C. [4 ]
Vittori, L. [4 ]
Mukhopadhyay, P. [5 ]
Massacesi, C. [6 ]
Sahmoud, T. [7 ]
Naughton, M. [8 ]
Andre, F. [9 ]
机构：
[1] Univ Calif Los Angeles, Sch Med, Internal Med Div Heme Onc, Los Angeles, CA USA
[2] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol, Atlanta, GA USA
[3] Ctr Reg Rene Gauducheau, Dept Oncol, St Herblain, France
[4] Novartis Pharma AG, Clin Res & Dev, BU Oncol, Basel, Switzerland
[5] Novartis Pharmaceut, Biostat Oncol BDM, Florham Pk, NJ USA
[6] Novartis Pharmaceut, Breast Canc RAD001, Florham Pk, NJ USA
[7] Novartis Pharmaceut, Global Oncol Dept, Florham Pk, NJ USA
[8] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA
[9] Inst Gustave Roussy, Dept Oncol Med Senol, Villejuif, France
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70913-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：267 / 267
页数：1
相关论文
共 50 条
  • [1] Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab
    Cardoso, F.
    Gianni, L.
    Jerusalem, G.
    Fasolo, A.
    Bergh, J.
    Dieras, V.
    Manlius, C.
    Mukhopadhyay, P.
    Massacesi, C.
    Sahmoud, T.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 261 - 261
  • [2] RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumah in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial
    O'Regan, R.
    Andre, F.
    Campone, M.
    Naughton, M.
    Manlius, C.
    Pylvaenaeinen, I
    Sahmoud, T.
    Hurvitz, S.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 237S - 237S
  • [3] Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
    Fasolo, A.
    Gianni, L.
    Rorive, A.
    Bergh, J.
    Dieras, V
    Cardoso, F.
    Vittori, L.
    Pylvaenaeinen, I
    Sahmoud, T.
    Jerusalem, G.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 93S - 93S
  • [4] Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
    Andre, F.
    Campone, M.
    Hurvitz, S. A.
    Vittori, L.
    Pylvaenaeinen, I.
    Sahmoud, T.
    O'Regan, R. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
    Jerusalem, G. H.
    Dieras, V.
    Cardoso, F.
    Bergh, J.
    Fasolo, A.
    Rorive, A.
    Manlius, C.
    Pylvaenaeinen, I.
    Sahmoud, T.
    Gianni, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Everolimus in combination with weekly paciltaxel and transtuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trail.
    Dalenc, F.
    Campone, M.
    Hupperets, P.
    O'Regan, R.
    Manlius, C.
    Vittori, L.
    Mukhopadhyay, P.
    Massacesi, C.
    Sahmoud, T.
    Andre, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
    Morrow, Phuong K.
    Wulf, Gerburg M.
    Ensor, Joe
    Booser, Daniel J.
    Moore, Julia A.
    Flores, Peter R.
    Xiong, Yan
    Zhang, Siyuan
    Krop, Ian E.
    Winer, Eric P.
    Kindelberger, David W.
    Coviello, Jeanna
    Sahin, Aysegul A.
    Nunez, Rodolfo
    Hortobagyi, Gabriel N.
    Yu, Dihua
    Esteva, Francisco J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (23) : 3126 - 3132
  • [8] Phase I trial of escalating doses of weekly everolimus (RAD001) in combination with docetaxel for the treatment of metastatic breast cancer (MBC)
    Moulder, S. L.
    Rivera, E.
    Ensor, J.
    Gonzalez-Angulo, A.
    Christofanilli, M.
    Booser, D.
    Giordano, S.
    Brewster, A.
    Hortobagyi, G.
    Tran, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer (MBC)
    Mayer, I. A.
    Means-Powell, J.
    Abramson, V. G.
    Shyr, Y.
    Balko, J. M.
    Kuba, M. G.
    Gharavii, H. M.
    Schlabach, L.
    Arteaga, C. L.
    Pietenpol, J. A.
    [J]. CANCER RESEARCH, 2011, 71
  • [10] Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    Esteva, FJ
    Valero, V
    Booser, D
    Guerra, LT
    Murray, JL
    Pusztai, L
    Cristofanilli, M
    Arun, B
    Esmaeli, B
    Fritsche, HA
    Sneige, N
    Smith, TL
    Hortobagyi, GN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) : 1800 - 1808
12345